Polymer Laboratories Inc - - BioPharm International

ADVERTISEMENT

Polymer Laboratories Inc

BioPharm International
Volume 18, Issue 12

Company Description



Polymer Laboratories (PL) specializes in developing and manufacturing high-grade polymeric particles for HPLC columns (nano through process-scale), solid- and solution-phase synthesis supports for high throughput organic synthesis and peptide synthesis; and polymers for clinical diagnostics, including paramagnetic particles for bioseparations.

PL's media and resins are manufactured under the ISO 9001:2000 Quality Management System.The company has 29 years' experience in polymers and polymer particles for high-technology applications.



PL is an international company with offices and laboratories in the US and Europe which, together with an established global distributor network, offer worldwide sales, technical support, and service.

Chief Biopharmaceutical Techniques Supported

  • Synthesis
  • Analysis
  • Purification

Facilities



State-of-the-art manufacturing facilities opened in 2001, with a capacity greater than 4 M tons of high- performance particles, establishing PL as one of the world's largest chromatographic and solid phase synthesis particle manufacturers. The company's facilities are ISO 9001:2000 accredited.

PL also provides stringently controlled specialized production of particles for biological applications.

Major Products

  • HPLC columns and media
  • Synthesis supports
  • Paramagnetic particles

Markets Served

  • Biotherapeutic synthesis and purification
  • Biomolecule synthesis and purification
  • Diagnostics

POLYMER LABORATORIES INC
Amherst Fields Research Park 160 Old Farm Road, Amherst, MA 01002

TELEPHONE
413.253.9554

FAX
413.253.2476

E-MAIL

WEB ADDRESS
http://www.polymerlabs.com/

EMPLOYEES
175 worldwide

FOUNDED
1976

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here